Compugen Ltd. reported second quarter 2026 financial results with revenues of approximately $2.6 million, up from $1.3 million in the prior year period, driven by recognition of upfront and milestone payments from its Gilead license agreement. The company incurred a net loss of approximately $7.0 million, or $0.07 per share, compared to a $7.3 million loss in Q2 2025. As of June 30, 2026, Compugen held approximately $125.3 million in cash and equivalents, providing a runway into 2029 with no debt. Clinically, the MAIA-ovarian trial for COM701 is on track for interim analysis data by Q1 2027, while partner AstraZeneca initiated an additional Phase 3 trial for rilvegostomig and presented first overall survival data from the GEMINI-Hepatobiliary study. Compugen operates in the clinical-stage cancer immunotherapy industry, utilizing AI/ML to discover and develop therapeutic antibodies.